Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis

Applied Radiation and Isotopes

Volumn 66, Issue 9, 2008, Pages 1196-1205

  Chakraborty, Sudipta ^a   Das, Tapas ^a   Sarma, Haladhar Dev ^a   Venkatesh, Meera ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

177Lu; Bone pain palliation; DOTMP; EDTMP

Indexed keywords

COMPARATIVE STUDIES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID LUTETIUM 177; LANTHANIDE; LEXIDRONAM LUTETIUM LU 177; LUTETIUM 177; PHOSPHONIC ACID DERIVATIVE; POLYAMINOPHOSPHONIC ACID; 177LU 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); 177LU-1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAKIS(METHYLENEPHOSPHONIC ACID); LUTETIUM; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG LIVER LEVEL; DRUG TRANSPORT; FEMALE; KIDNEY CLEARANCE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOCHEMISTRY; RADIOISOTOPE DECAY; RADIOISOTOPE DISTRIBUTION; RAT; TISSUE DISTRIBUTION; ANIMAL; BONE TUMOR; DRUG STABILITY; PAIN; PALLIATIVE THERAPY; WISTAR RAT;

ANIMALS; BONE NEOPLASMS; DRUG STABILITY; LUTETIUM; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; PALLIATIVE CARE; RABBITS; RADIOISOTOPES; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 47749088624     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.02.061     Document Type: Article

References (40)

1. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl. Med. Commun. 19 (1998) 587-591
2. 105Rh-EDTMP and its bone accumulation. Appl. Radiat. Isot. 52 (2000) 211-215
3. Awasthi V., Meinken G., Springer K., Srivastava S.C., and Freimuth P. Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice. J. Virol. 78 (2004) 6431-6438
4. Bayouth J.E., Macey D.J., Kasi L.P., Garlich J.R., MacMillan K., Dimopoulos M.A., and Champlin R.E. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J. Nucl. Med. 36 (1995) 730-737
5. 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J. Nucl. Med. 41 (2000) 2043-2050
6. Bouchet L.G., Bolch W.E., Goddu S.M., Howell R.W., and Rao D.V. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med. 41 (2000) 682-687
7. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J. Nucl. Med. 47 (2006) 534-542
8. Caravan P., Ellison J.J., McMurry T.J., and Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications. Chem. Rev. 99 (1999) 2293-2352
9. 177Lu-labeled polyaminophosphonates as potential agents for bone pain palliation. Nucl. Med. Commun. 23 (2002) 67-74
10. 177Lu labeled hydroxyapatite as a promising agent for radiation synovectomy of small joints. Nucl. Med. Commun. 27 (2006) 661-668
11. Collins C., Eary J.F., Donaldson G., Vernon C., Bush N.E., Petersdorf S., Livingston R.B., Gordon E.E., Chapman C.R., and Appelbaum F.R. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase-I/II trial. J. Nucl. Med. 34 (1993) 1839-1844
12. 177Lu labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl. Radiat. Isot. 57 (2002) 177-184
13. 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. Bioorg. Med. Chem. 12 (2004) 6077-6084
14. 177Lu labeled metronidazole for possible use in targeting tumor hypoxia. Radiochim. Acta 94 (2006) 375-380
15. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis. Radiochim. Acta 96 (2008) 55-61
16. Deligny C.L., Gelsema W.J., Tji T.G., Huigen Y.M., and Vink H.A. Bone seeking radiopharmaceuticals. Nucl. Med. Biol. 17 (1990) 164-179
17. 32P-orthophosphate: implications of therapy of bone pain and bone metastases. J. Nucl. Med. 41 (2000) 941-951
18. Goeckeler W.F., Troutner D.E., Volkert W.A., Edwards B., Simon J., and Wilson D. Sm-153: radiotherapeutic bone agents. Nucl. Med. Biol. 13 (1986) 479-482
19. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., and Winston D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J. Nucl. Med. 28 (1987) 495-504
20. Hosain F., and Spencer R.P. Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin. Nucl. Med. 22 (1992) 11-16
21. Hoskin P.J. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat. Rev. 29 (2003) 321-327
22. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl. Med. Biol. 14 (1987) 223-232
23. 153Sm-EDTMP in a dog with spontaneous osteosarcoma. Eur. J. Nucl. Med. 29 (2002) 191-197
24. 153Sm in rats. Appl. Radiat. Isot. 45 (1994) 949-953
25. Lewington V.J. Bone seeking radionuclides for therapy. J. Nucl. Med. 46 (2005) 38S-47S
26. Liu S., and Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug. Chem. 12 (2001) 7-34
27. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur. J. Nucl. Med. Mol. Imag. 31 Suppl. 1 (2004) S171-S178
28. McEwan A.J. Pain from metastatic bone tumors. In: Aktolun C., and Tauxe W.N. (Eds). Nuclear Oncology (1999), Springer, Berlin, Hiedelberg 245-260
29. Moedrizer K., and Irani R. The direct synthesis of α-aminomethyl phosphonic acids. Mannich-type reactions with orthophosphorus acids. J. Org. Chem. 31 (1966) 1603-1607
30. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Jthakissos D.S., and Avagoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int. J. Pharm. 221 (2001) 143-152
31. Pandit-Taskar N., Batraki M., and Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastasis. J. Nucl. Med. 45 (2004) 1358-1365
32. 177Lu for radionuclide therapy. Appl. Radiat. Isot. 59 (2003) 109-117
33. Pulukkody K.P., Norman T.J., Parker D., Royle L., and Broan C.J. Synthesis of charged and uncharged complexes of gadolinium and yttrium with cyclic polyazaphosphinic acid ligands for in vivo applications. J. Chem. Soc. Perkin Trans. (1993) 605-620
34. 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J. Nucl. Med. 43 (2002) 1383-1390
35. Serafini A.N. Systematic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Q. J. Nucl. Med. Mol. Imag. 45 (2001) 91-99
36. Silberstein E.B. Dosage and response in the radiopharmaceutical therapy of painful osseous metastases. J. Nucl. Med. 37 (1996) 249-252
37. Singh A., Holmes R.A., Farhangi M., Volkert W.A., Williams A., Stringham L.M., and Ketring A.R. Human pharmacokinetics of Samarium-153-EDTMP in metastatic cancer. J. Nucl. Med. 30 (1989) 1814-1818
38. Sola G.A.R., Arguelles M.G., Bottazzini D.L., Furnari J.C., Parada I.G., Rojo A., and Ruiz H.V. Lutetium-177-EDTMP for bone pain palliation. Preparation, biodistribution and preclinical studies. Radiochim. Acta 88 (2000) 157-161
39. Twycross R.G., and Fairfield S. Pain in far advanced cancer. Pain 14 (1982) 303-310
40. Volkert W.A., and Hoffman T.J. Therapeutic radiopharmaceuticals. Chem. Rev. 99 (1999) 2269-2292